Our commitment: Stop the progression of proteinuric CKD

Walden Biosciences is a clinical-stage company dedicated to developing disease-modifying treatments that dramatically improve the outlook for people with proteinuric CKD. Our goal is to prevent kidney damage and stop disease progression in rare proteinuric kidney diseases, such as FSGS, IgAN, MN, and Alport syndrome.

Walden’s development programs have the potential to achieve this goal because they directly address underlying mechanisms that cause proteinuria across these diseases, as well as the more common forms of proteinuric kidney disease.